Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by StevenBirchon Dec 09, 2024 10:33am
161 Views
Post# 36352605

RE:RE:RE:RE:Investor Presentation [12-2024]

RE:RE:RE:RE:Investor Presentation [12-2024]It sure looks that way. Looking at the BTD process, after the first pre-BTD the FDA wanted Post Study II Monitoring Of Response and Central Pathology Lab Review and after the second pre-BTD the FDA asked for a different format to present the clinical data to better align with clinical data supplied by other companies. By "other companies" do they mean ones that have already been approved? Being this late in the process that's what I would think and that would have to be a positive.


Lesalpes29 wrote: BTD-Accelerared approval could be closer than we think. Problably why they are opening new sites. The only explanation that I can speculate on! GL


<< Previous
Bullboard Posts
Next >>